[et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”Header” _builder_version=”4.27.4″ use_background_color_gradient=”on” background_color_gradient_type=”circular” background_color_gradient_direction_radial=”top left” background_color_gradient_stops=”rgba(121,45,140,0.89) 20%|rgba(0,56,94,0) 100%” background_color_gradient_overlays_image=”on” background_color_gradient_start=”rgba(0,39,91,0.75)” background_color_gradient_start_position=”19%” background_color_gradient_end=”rgba(0,56,94,0)” background_image=”https:\/\/alipanc.org\/wp-content\/uploads\/bfdc8541-cae4-424f-ae2f-a2468e8d86ab.jpg.png” min_height=”198.5px” custom_padding=”0vh|0|0vh||false|false” custom_padding_tablet=”10vh||10vh||false” custom_padding_phone=”5vh|0|11vh||false|false” top_divider_style=”curve” top_divider_color=”rgba(12,113,195,0.11)” top_divider_height=”75%” top_divider_repeat=”1x” top_divider_flip=”horizontal” top_divider_height_tablet=”41%” top_divider_height_phone=”26%” top_divider_height_last_edited=”on|phone” bottom_divider_color=”#ffffff” bottom_divider_height=”3vw” bottom_divider_flip=”vertical” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_row _builder_version=”4.16″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.18.1″ text_font=”||||||||” ul_font=”||||||||” ol_font=”||||||||” header_font=”|700|||||||” header_font_size=”64px” header_letter_spacing=”1px” header_line_height=”1.2em” header_2_font=”||||||||” header_2_font_size=”33px” header_2_letter_spacing=”1px” header_2_line_height=”1.4em” header_3_font=”||||||||” header_4_font=”||||||||” header_5_font=”||||||||” header_6_font=”||||||||” background_layout=”dark” module_alignment=”left” custom_margin=”||20px|” animation_style=”slide” animation_direction=”left” animation_intensity_slide=”2%” header_font_size_tablet=”64px” header_font_size_phone=”42px” header_font_size_last_edited=”on|phone” header_2_font_size_tablet=”36px” header_2_font_size_phone=”32px” header_2_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_text content_tablet=”<\/p>\n
Join our journey to unravel the mysteries of pancreatic cancer through innovative projects and multidisciplinary collaborations.<\/p>\n
” content_phone=”<\/p>\n
Join our journey to unravel the mysteries of pancreatic cancer through innovative projects and multidisciplinary collaborations.<\/p>\n
” content_last_edited=”on|desktop” _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_font_size=”19px” text_line_height=”1.6em” background_layout=”dark” custom_margin=”-21px|||||” text_text_shadow_style=”preset3″ global_colors_info=”{}”]<\/p>\n
Join our journey to unravel the mysteries of pancreatic cancer through innovative projects and multidisciplinary collaborations.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”About” _builder_version=”4.25.1″ _module_preset=”default” custom_margin=”0px|||||” custom_padding=”0px|||||” collapsed=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”26px||6px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”Clinical and molecular predictors of long survival in pancreatic cancer: a multicenter and multidisciplinary study (ALIPANC-LTS)” open_toggle_text_color=”#792D8C” icon_color=”#792D8C” _builder_version=”4.27.4″ _module_preset=”default” title_text_color=”#792D8C” title_font=”||||||||” title_font_size=”19px” closed_title_font_size=”19px” global_colors_info=”{}”]<\/p>\n
Principal investigators: <\/span>Florian Castet, Andr\u00e9s Mu\u00f1oz and Ana Mar\u00eda Jim\u00e9nez Gordo.<\/span><\/span><\/p>\n Involved centers and collaborating entities: <\/span>Vall d’Hebron Institut d’Oncologia (VHIO), Hospital universitario Gregorio Mara\u00f1\u00f3n (HUGM) and Hospital Universitario Infanta Sof\u00eda (HUIS).<\/span><\/p>\n Objectives: <\/span>To study the epidemiological, clinical and biological characteristics of long surviving patients (LS) of pancreatic adenocarcinoma (ADP) compared with a group of similar patients with a shorter survival. To advance in the knowledge of the characteristics that may have been involved in their long survival. <\/span><\/span><\/p>\n Project Description:<\/span><\/p>\n We start from the hypothesis that long-surviving ADP patients have differential characteristics that confer them a better prognosis. <\/span><\/span><\/p>\n A series of ADP LS patients have been selected and will be fully analyzed from a clinical and molecular point of view. A clinical database and federated biobank of LS patient samples has been created. They will be compared with a group of similar characteristics, but with shorter survivals. The determination of GATA6, CKT5\/6, S100A2 and p63 on TMAs of all patients will be performed at CNIO to identify the molecular subtypes and to validate their clinical and therapeutic implications. Subsequently, further analyses can be performed in this series of patients to advance our knowledge of the disease.<\/span><\/span><\/p>\n [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”2px||7px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”Optimization of adjuvant treatment of pancreatic cancer according to the molecular subtype determined by immunohistochemical biomarkers (OPTIPANC study)” open_toggle_text_color=”#792D8C” icon_color=”#792D8C” _builder_version=”4.27.4″ _module_preset=”default” title_text_color=”#792D8C” title_font=”||||||||” title_font_size=”19px” closed_title_font_size=”19px” global_colors_info=”{}”]<\/p>\n Principal investigators:<\/span> Jaime Feliu.<\/span><\/span><\/p>\n Centers involved and collaborating entities: <\/span>Hospitals La Paz (H La Paz), Doce de Octubre, Puerta de Hierro, Hospital Cl\u00ednico de Barcelona, Infanta Sof\u00eda, Gregorio Mara\u00f1\u00f3n (HUGM) and Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO).<\/span><\/p>\n Objectives: <\/span>The aim of this project is to determine whether adjuvant chemotherapy (QT), administered according to molecular subtype, can improve disease-free survival (DFS) and overall survival (OS) of patients operated on for pancreatic adenocarcinoma (PAD). This is a retrospective, multicenter study that will include 422 patients operated on for ADP and treated with adjuvant QT who have adequate follow-up, clinical data and tumor samples. The molecular subtype will be determined by immunohistochemistry (IHQ) techniques (GATA6, GATA4, E-cadherin and Cytokeratins 5, 14 and 17). Subsequently, molecular subtype will be correlated with EFS, OS and with the QT administered. 151 patients treated with mFOLFIRINOX, 146 with Gemcitabine – Capecitabine and 125 with Gemcitabine will be included. <\/span><\/p>\n Project Description:<\/span><\/p>\n The only curative treatment for adenocarcinoma of the pancreas (ADP) is surgery, but 80% of patients relapse after surgery. Adjuvant chemotherapy (QT) increases disease-free survival (DFS) and overall survival (OS), but despite recent advances, 60% of patients will still relapse within 3 years of surgery. Moreover, there are no established criteria for selecting the type of QT beyond ECOG PS. <\/span><\/span><\/p>\n Recently, several molecular classifications in ADP have been proposed, but all of them recognize two molecular subtypes: classical and basal-like, with different sensitivity to QT: while the former would respond better to mFOLFIRINOX, the latter would respond better to gemcitabine. <\/span><\/span><\/p>\n The results will make it possible to optimize adjuvant treatment, thus improving survival and increasing the proportion of long survivors.<\/span><\/p>\n This project involves the participation of the following hospitals: La Paz, Doce de Octubre, Puerta de Hierro, Cl\u00ednico de Barcelona, Infanta Sof\u00eda, Princesa, Gregorio Mara\u00f1\u00f3n and the CNIO.<\/span><\/p>\n [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”2px||8px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”Study of new drugs and development of immunotherapeutic approaches for the treatment of PDAC” open_toggle_text_color=”#792D8C” icon_color=”#792D8C” _builder_version=”4.27.4″ _module_preset=”default” title_text_color=”#792D8C” title_font=”||||||||” title_font_size=”19px” closed_title_font_size=”19px” global_colors_info=”{}”]<\/p>\n Principal Investigators: <\/span>\u00c1frica Gonz\u00e1lez Fern\u00e1ndez and Rosana Sim\u00f3n V\u00e1zquez <\/span><\/span><\/p>\n Involved centers and collaborating entities: <\/span>Laboratory of Immunology-Center for Research in Nanomaterials and Biomedicine (CINBIO), University of Girona, National Cancer Research Center (CNIO), National Network of Cancer Immunotherapy (REINCA), National Network of Advanced Therapies (TERAV+).<\/span><\/p>\n Objectives: <\/span>Design of lipoplexes for gene silencing of transcription factors involved in pathways for pancreatic cancer proliferation and resistance, development of monoclonal antibodies and design of CAR-T cell-based immunotherapy.<\/span><\/p>\n Collaborations are requested with groups working on the development of new therapies or drugs, with experience in the development of advanced tumor models, the CRISPR\/Cas system and the use of viral vectors.<\/span><\/p>\n Project Description:<\/span><\/p>\n Experience offered. In our group we have developed: <\/span><\/p>\n Collaborations requested:<\/span><\/p>\n Current financing:<\/span><\/span><\/p>\n Future financing plan: <\/span><\/span><\/p>\n request for funding through foundations (Caixa, BBVA…), companies and national and European public bodies.<\/span><\/p>\n Current collaborations: <\/span><\/span><\/p>\n [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”2px||8px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”PanGen-Asma and Guide” open_toggle_text_color=”#792D8C” icon_color=”#792D8C” _builder_version=”4.27.4″ _module_preset=”default” title_text_color=”#792D8C” title_font=”||||||||” title_font_size=”19px” closed_title_font_size=”19px” custom_margin=”||-6px|||” global_colors_info=”{}”]<\/p>\n Principal Investigators: <\/span>Evangelina L\u00f3pez de Marutana and N\u00faria Malats.<\/span><\/p>\n Involved centers and collaborating entities: <\/span>Genetic and Molecular Epidemiology Group (GMEG) – Spanish National Cancer Research Center (CNIO).<\/span><\/p>\n Objectives<\/span>: <\/span>This is an observational study aimed at exploring associations between omics data (1) genomic data at the germline level, 2) circulating blood leukocyte DNA methylation, 3) oral, fecal and tumor microbiome, 4) metabolome in urine, serum and feces, and 5) tumor transcriptome), and non-omics, including epidemiological data, biomarkers such as IgEs or neutrophil to eosinophil ratios, to shed light on the relationship between asthma and allergies and pancreatic cancer risk. <\/span><\/p>\n Project Description:<\/span><\/p>\n Epidemiological study funded by the Fondo de Investigaci\u00f3n Sanitaria (PI21\/00495) in the framework of the project \u201cDeciphering the complex relationship between asthma\/allergy and pancreatic cancer risk\u201d and whose principal investigators are Dr. N\u00faria Malats Riera (leader) and Dr. Evangelina L\u00f3pez de Maturana L\u00f3pez de Lacalle (researcher) of the Genetic and Molecular Epidemiology group of the CNIO.<\/span><\/p>\n [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”2px||10px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”Validation of AXL as a biomarker for pancreatic cancer detection” open_toggle_text_color=”#792D8C” icon_color=”#792D8C” _builder_version=”4.27.4″ _module_preset=”default” title_text_color=”#792D8C” title_font=”||||||||” title_font_size=”19px” closed_title_font_size=”19px” custom_margin=”3px||-4px|||” global_colors_info=”{}”]<\/p>\n Principal Investigators: <\/span>Pilar Navarro and Neus Mart\u00ednez-Bosch<\/span><\/p>\n Involved centers and collaborating entities: <\/span>Hospital del Mar de Investigaciones M\u00e9dicas (IMIM), Instituto de Investigaciones Biomedicas- Centro Superior de Investigaciones Cient\u00edficas (IIBB-CSIC), University of Santiago de Compostela, University of Zaragoza, Institut d’Investigaci\u00f3 Biom\u00e8dica de Girona Dr. Josep Trueta (UdG), Vall d’Hebron Institute of Oncology (VHIO).<\/span><\/p>\n Objectives: <\/span><\/span><\/p>\n Our current goal is to generate an accurate AXL-based method to diagnose pancreatic cancer early. <\/span><\/span><\/p>\n Description of the study: firstly, we will validate the use of sAXL as a biomarker in blood by extending the analysis to a large number of samples (\u2265500), through a multicenter retroprospective study, in order to strengthen the results and establish an accurate \u201ccut-off\u201d to transfer the determination of sAXL in plasma by ELISA as a diagnostic test in clinical practice. In addition, in parallel we intend to produce a serological test based on LFIA to optimize the decentralized diagnostic use in patients at risk. Taking into account the low invasiveness (blood test) and the simplicity and low cost of these tests, we consider that this project has a high potential in the clinical setting of pancreatic cancer. <\/span><\/p>\n Project Description:<\/span><\/p>\n Pancreatic cancer<\/b> is one of the most aggressive tumors, being the third leading cause of cancer death. One of the reasons for this terrible scenario is late diagnosis: 80% of patients are diagnosed when the tumor has spread and is inoperable, being highly refractory to available therapies<\/b>. It should be emphasized that the 5-year survival of patients with resectable tumors is >40% while that of those with metastatic tumors is <5%. Therefore, the identification of early biomarkers is essential to improve survival. Our team has recently identified the detection of sAXL in plasma as a biomarker for the detection of pancreatic cancer <\/b>(Martinez-Bosch et al, eBioMed 2022), observing the increase of sAXL from early stages of the disease. Furthermore, the combination of sAXL with the only marker so far approved for this tumor, CA19-9, achieves high sensitivity and specificity. These results demonstrate that sAXL may be a promising new biomarker for the early detection of pancreatic cancer and that its use in combination with CA19-9 could be a diagnostic test for clinical use. <\/span><\/p>\n This project has been made possible in part thanks to the Carmen Delgado\/Miguel P\u00e9rez-Mateo<\/b> Grant for Pancreatic Cancer Research, organized by the Pancreatic Cancer Association (ACANPAN), the Spanish Association of Pancreatology (AESPANC) and the Spanish Association of Gastroenterology (AEG). The funds for the Scholarships are obtained thanks to all the participants of the Cities Race against pancreatic cancer. <\/span><\/span><\/p>\n Agradecemos enormemente a todos los grupos de ALIPANC<\/b> que han contribuido y mostrado inter\u00e9s en el proyecto contado con colaboradores desde la Universidad Santiago de Compostela, Universidad de Zaragoza, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Girona Dr. Josep Trueta, Universitat de Girona, Vall d’Hebron Institute of Oncology (VHIO), Institut d’Investigaci\u00f3 en Ci\u00e8ncies de la Salut Germans Trias i Pujol, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Hospital Universitario La Paz, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante and Instituto de Investigaci\u00f3n Sanitaria Valencia.<\/span><\/p>\n [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”2px|||||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”Guide.MRD” open_toggle_text_color=”#792D8C” icon_color=”#792D8C” _builder_version=”4.27.4″ _module_preset=”default” title_text_color=”#792D8C” title_font=”||||||||” title_font_size=”19px” closed_title_font_size=”19px” global_colors_info=”{}”]<\/p>\n Principal investigators:<\/span> IHI JU<\/span><\/a> (European Union)<\/span><\/span><\/p>\n Involved centers and collaborating entities:<\/span> IHI JU<\/span><\/a><\/span>, Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO).<\/span><\/p>\n Objectives: <\/span>This is a precision oncology project that seeks to improve the usefulness and clinical implementation of circulating tumor DNA (ctDNA) as a biomarker of minimal residual disease to predict clinical response and to choose the most appropriate multimodal therapy for patients with malignant solid tumors such as colon, lung and pancreas.<\/span><\/p>\n Project Description:<\/span><\/p>\n International project funded by the Innovative Health Initiative Joint Undertaken (No 101112066), whose participants come from academia (including CNIO), medical technology, pharmaceuticals, as well as patient advocacy organizations (Homepage – GUIDE.MRD<\/span><\/a>).<\/span><\/p>\n [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Our ProjectsJoin our journey to unravel the mysteries of pancreatic cancer through innovative projects and multidisciplinary collaborations.Principal investigators: Florian Castet, Andr\u00e9s Mu\u00f1oz and Ana Mar\u00eda Jim\u00e9nez Gordo. Involved centers and collaborating entities: Vall d’Hebron Institut d’Oncologia (VHIO), Hospital universitario Gregorio Mara\u00f1\u00f3n (HUGM) and Hospital Universitario Infanta Sof\u00eda (HUIS). Objectives: To study the epidemiological, clinical and […]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"class_list":["post-2080","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/pages\/2080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/comments?post=2080"}],"version-history":[{"count":5,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/pages\/2080\/revisions"}],"predecessor-version":[{"id":2529,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/pages\/2080\/revisions\/2529"}],"wp:attachment":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/media?parent=2080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n
\n